English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As the indications for endoscopic diagnosis and therapy continue to expand, an increasing number of patients receiving anticoagulants and antiplatelet agents will be encountered in gastroenterology practice. The management of these patients at the time of elective endoscopy can be challenging. Furthermore, this population has not been well studied, and thus, current guidelines are largely based on expert opinion. Ultimately, the risk of bleeding must be weighed against the risk of thromboembolic events when deciding whether to reverse anticoagulation or discontinue antiplatelet therapy before endoscopy. The present paper discusses three scenarios to highlight the authors’ own clinical practice, and reviews the current published guidelines on this topic.

Management of Anticoagulants and Antiplatelet Agents in Elective Endoscopy: Weighing the Risks and Benefits